Prenatal selective serotonin reuptake inhibitor use and the risk of autism spectrum disorder in children: A systematic review and meta-analysis

Reproductive Toxicology

Volumn 66, Issue , 2016, Pages 31-43

  Kaplan, Yusuf C ^a,b   Keskin Arslan, Elif ^a,b   Acar, Selin ^a,b   Sozmen, Kaan ^a  

^a IZMIR KATIP CELEBI UNIVERSITY   (Turkey)

^b Division of Rheumatology   (Turkey)

Author keywords

Antidepressants; Antidepressive agents; Autism; Autism spectrum disorder; Autistic disorder; Pregnancy; Serotonin uptake inhibitors; SSRI

Indexed keywords

SEROTONIN UPTAKE INHIBITOR;

ANALYTIC METHOD; ARTICLE; AUTISM; CASE CONTROL STUDY; CHILD; COHORT ANALYSIS; DEPRESSION; DRUG USE; HUMAN; META ANALYSIS; MOTHER; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PREGNANCY; PRENATAL DRUG EXPOSURE; RISK ASSESSMENT; SYSTEMATIC REVIEW; FEMALE; PRENATAL EXPOSURE; RISK;

AUTISM SPECTRUM DISORDER; CHILD; FEMALE; HUMANS; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; RISK; SEROTONIN UPTAKE INHIBITORS;

EID: 84988726316     PISSN: 08906238     EISSN: 18731708     Source Type: Journal    
DOI: 10.1016/j.reprotox.2016.09.013     Document Type: Article

References (81)

1. [1] Alder, J., Fink, N., Bitzer, J., Hösli, I., Holzgreve, W., Depression and anxiety during pregnancy: a risk factor for obstetric, fetal and neo- natal outcome? A critical review of the literature. J. Matern. Fetal Neonatal Med. 20:3 (2007), 189–209.
2. [2] Gentile, S., Untreated depression during pregnancy: short- and long-term effects in offspring. A systematic review. Neuroscience, 2015 S0306-4522(15)00811-8.
3. [3] Pawlby, S., Hay, D.F., Sharp, D., Waters, C.S., O'Keane, V., Antenatal depression predicts depression in adolescent offspring: prospective longitudinal community-based study. J. Affect. Disord. 113:3 (2009), 236–243.
4. [4] Kim, D.R., Sockol, L.E., Sammel, M.D., Kelly, C., Moseley, M., Epperson, C.N., Elevated risk of adverse obstetric outcomes in pregnant women with depression. Arch. Womens Ment. Health 16:6 (2013), 475–482.
5. [5] Grote, N.K., Bridge, J.A., Gavin, A.R., Melville, J.L., Iyengar, S., Katon, W.J., A meta-analysis of depression during pregnancy and the risk of preterm birth, low birth weight, and intrauterine growth restriction. Arch. Gen. Psychiatry 67:10 (2010), 1012–1024.
6. [6] Latendresse, G., Wong, B., Dyer, J., Wilson, B., Baksh, L., Hogue, C., Duration of maternal stress and depression: predictors of newborn admission to neonatal intensive care unit and postpartum depression. Nurs. Res. 64:5 (2015), 331–341.
7. [7] Ashley, J.M., Harper, B.D., Arms-Chavez, C.J., LoBello, S.G., Estimated prevalence of antenatal depression in the US population. Arch. Womens Ment. Health 19:2 (2016), 395–400.
8. [8] Bennett, H.A., Einarson, A., Taddio, A., Koren, G., Einarson, T.R., Prevalence of depression during pregnancy: systematic review. Obstet. Gynecol. 103:4 (2004), 698–709.
9. [9] Zoega, H., Kieler, H., Nørgaard, M., et al. Use of SSRI and SNRI antidepressants during pregnancy: a population-based study from Denmark, Iceland, Norway and Sweden. PLoS One, 10(12), 2015, e0144474.
10. [10] Margulis, A.V., Kang, E.M., Hammad, T.A., Patterns of prescription of antidepressants and antipsychotics across and within pregnancies in a population-based UK cohort. Matern. Child Health J. 18:7 (2014), 1742–1752.
11. [11] Alwan, S., Reefhuis, J., Rasmussen, S.A., Friedman, J.M., Patterns of antidepressant medication use among pregnant women in a United States population. J. Clin. Pharmacol. 51:2 (2011), 264–270.
12. [12] Huybrechts, K.F., Palmsten, K., Mogun, H., et al. National trends in antidepressant medication treatment among publicly insured pregnant women. Gen. Hosp. Psychiatry 35:3 (2013), 265–271.
13. [13] Cooper, W.O., Willy, M.E., Pont, S.J., Ray, W.A., Increasing use of antidepressants in pregnancy. Am. J. Obstet. Gynecol., 196(6), 2007 544. e1-5.
14. [14] Nakhai-Pour, H.R., Broy, P., Bérard, A., Use of antidepressants during pregnancy and the risk of spontaneous abortion. CMAJ 182:10 (2010), 1031–1037.
15. [15] Palmsten, K., Hernández-Díaz, S., Huybrechts, K.F., et al. Use of antidepressants near delivery and risk of postpartum hemorrhage: cohort study of low income women in the United States. BMJ, 347, 2013, f4877.
16. [16] Wisner, K.L., Sit, D.K., Hanusa, B.H., et al. Major depression and antidepressant treatment: impact on pregnancy and neonatal outcomes. Am. J. Psychiatry 166:5 (2009), 557–566.
17. [17] Chambers, C.D., Hernandez-Diaz, S., Van Marter, L.J., et al. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N. Engl. J. Med. 354:6 (2006), 579–587.
18. [18] Bérard, A., Zhao, J.P., Sheehy, O., Sertraline use during pregnancy and the risk of major malformations. Am. J. Obstet. Gynecol., 212(6), 2015 795. e1–795. e12.
19. [19] Andersen, J.T., Andersen, N.L., Horwitz, H., Poulsen, H.E., Jimenez-Solem, E., Exposure to selective serotonin reuptake inhibitors in early pregnancy and the risk of miscarriage. Obstet. Gynecol. 124:4 (2014), 655–661.
20. [20] Lupattelli, A., Spigset, O., Koren, G., Nordeng, H., Risk of vaginal bleeding and postpartum hemorrhage after use of antidepressants in pregnancy: a study from the Norwegian Mother and Child Cohort Study. J. Clin. Psychopharmacol. 34:1 (2014), 143–148.
21. [21] Malm, H., Sourander, A., Gissler, M., et al. Pregnancy complications following prenatal exposure to SSRIs or maternal psychiatric disorders: results from population-based national register data. Am. J. Psychiatry 172:12 (2015), 1224–1232.
22. [22] Huybrechts, K.F., Bateman, B.T., Palmsten, K., et al. Antidepressant use late in pregnancy and risk of persistent pulmonary hypertension of the newborn. JAMA 313:21 (2015), 2142–2151.
23. [23] Nordeng, H., van Gelder, M.M., Spigset, O., Koren, G., Einarson, A., Eberhard-Gran, M., Pregnancy outcome after exposure to antidepressants and the role of maternal depression: results from the Norwegian Mother and Child Cohort Study. J. Clin. Psychopharmacol. 32:2 (2012), 186–194.
24. [24] Johansen, R.L., Mortensen, L.H., Andersen, A.M., Hansen, A.V., Strandberg-Larsen, K., Maternal use of selective serotonin reuptake inhibitors and risk of miscarriage − assessing potential biases. Paediatr. Perinat. Epidemiol. 29:1 (2015), 72–81.
25. [25] Grigoriadis, S., The effects of antidepressant medications on mothers and babies. J. Popul. Ther. Clin. Pharmacol. 21:3 (2014), e533–541.
26. [26] Oberlander, T.F., Misri, S., Fitzgerald, C.E., Kostaras, X., Rurak, D., Riggs, W., Pharmacologic factors associated with transient neonatal symptoms following prenatal psychotropic medication exposure. J. Clin. Psychiatry 65:2 (2004), 230–237.
27. [27] Moses-Kolko, E.L., Bogen, D., Perel, J., et al. Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: literature review and implications for clinical applications. JAMA 293:19 (2005), 2372–2383.
28. [28] Nulman, I., Rovet, J., Stewart, D.E., et al. Neurodevelopment of children exposed in utero to antidepressant drugs. N. Engl. J. Med. 336:4 (1997), 258–262.
29. [29] Nulman, I., Rovet, J., Stewart, D.E., et al. Child development following exposure to tricyclic antidepressants or fluoxetine throughout fetal life: a prospective, controlled study. Am. J. Psychiatry 159:11 (2002), 1889–1895.
30. [30] Nulman, I., Koren, G., Rovet, J., et al. Neurodevelopment of children following prenatal exposure to venlafaxine, selective serotonin reuptake inhibitors, or untreated maternal depression. Am. J. Psychiatry 169:11 (2012), 1165–1174.
31. [31] Nulman, I., Koren, G., Rovet, J., Barrera, M., Streiner, D.L., Feldman, B.M., Neurodevelopment of children prenatally exposed to selective reuptake inhibitor antidepressants: toronto sibling study. J. Clin. Psychiatry 76:7 (2015), e842–847.
32. [32] Austin, M.P., Karatas, J.C., Mishra, P., Christl, B., Kennedy, D., Oei, J., Infant neurodevelopment following in utero exposure to antidepressant medication. Acta Paediatr. 102:11 (2013), 1054–1059.
33. [33] Casper, R.C., Fleisher, B.E., Lee-Ancajas, J.C., et al. Follow-up of children of depressed mothers exposed or not exposed to antidepressant drugs during pregnancy. J. Pediatr. 142:4 (2003), 402–408.
34. [34] Casper, R.C., Gilles, A.A., Fleisher, B.E., Baran, J., Enns, G., Lazzeroni, L.C., Length of prenatal exposure to selective serotonin reuptake inhibitor (SSRI) antidepressants: effects on neonatal adaptation and psychomotor development. Psychopharmacology (Berl) 217:2 (2011), 211–219.
35. [35] Hanley, G.E., Brain, U., Oberlander, T.F., Infant developmental outcomes following prenatal exposure to antidepressants, and maternal depressed mood and positive affect. Early Hum. Dev. 89:8 (2013), 519–524.
36. [36] Brandlistuen, R.E., Ystrom, E., Eberhard-Gran, M., Nulman, I., Koren, G., Nordeng, H., Behavioural effects of fetal antidepressant exposure in a Norwegian cohort of discordant siblings. Int. J. Epidemiol. 44:4 (2015), 1397–1407.
37. [37] Clements, C.C., Castro, V.M., Blumenthal, S.R., et al. Prenatal antidepressant exposure is associated with risk for attention-deficit hyperactivity disorder but not autism spectrum disorder in a large health system. Mol. Psychiatry 20:6 (2015), 727–734.
38. [38] Misri, S., Reebye, P., Kendrick, K., et al. Internalizing behaviors in 4-year-old children exposed in utero to psychotropic medications. Am. J. Psychiatry 163:6 (2006), 1026–1032.
39. [39] Oberlander, T.F., Papsdorf, M., Brain, U.M., Misri, S., Ross, C., Grunau, R.E., Prenatal effects of selective serotonin reuptake inhibitor antidepressants, serotonin transporter promoter genotype (SLC6A4), and maternal mood on child behavior at 3 years of age. Arch. Pediatr. Adolesc. Med. 164:5 (2010), 444–451.
40. [40] Figueroa, R., Use of antidepressants during pregnancy and risk of attention-deficit/hyperactivity disorder in the offspring. J. Dev. Behav. Pediatr. 31:8 (2010), 641–648.
41. [41] Laugesen, K., Olsen, M.S., Telén Andersen, A.B., Frøslev, T., Sørensen, H.T., In utero exposure to antidepressant drugs and risk of attention deficit hyperactivity disorder: a nationwide Danish cohort study. BMJ Open, 3(9), 2013, e003507.
42. [42] Gur, T.L., Kim, D.R., Epperson, C.N., Central nervous system effects of prenatal selective serotonin reuptake inhibitors: sensing the signal through the noise. Psychopharmacology (Berl) 227:4 (2013), 567–582.
43. [43] Muller, C.L., Anacker, A.M., Veenstra-VanderWeele, J., The serotonin system in autism spectrum disorder: from biomarker to animal models. Neuroscience, 2015 S0306-4522(15)00999-9.
44. [44] Schain, R.J., Freedman, D.X., Studies on 5-hydroxyindole metabolism in autistic and other mentally retarded children. J. Pediatr. 58 (1961), 315–320.
45. [45] Hanley, H.G., Stahl, S.M., Freedman, D.X., Hyperserotonemia and amine metabolites in autistic and retarded children. Arch. Gen. Psychiatry 34:5 (1977), 521–531.
46. [46] Mulder, E.J., Anderson, G.M., Kema, I.P., et al. Platelet serotonin levels in pervasive developmental disorders and mental retardation: diagnostic group differences, within-group distribution, and behavioral correlates. J. Am. Acad. Child Adolesc. Psychiatry 43:4 (2004), 491–499.
47. [47] Gabriele, S., Sacco, R., Persico, A.M., Blood serotonin levels in autism spectrum disorder: a systematic review and meta-analysis. Eur. Neuropsychopharmacol. 24:6 (2014), 919–929.
48. [48] Croen, L.A., Grether, J.K., Yoshida, C.K., Odouli, R., Hendrick, V., Antidepressant use during pregnancy and childhood autism spectrum disorders. Arch. Gen. Psychiatry 68:11 (2011), 1104–1112.
49. [49] Eriksson, M.A., Westerlund, J., Anderlid, B.M., Gillberg, C., Fernell, E., First-degree relatives of young children with autism spectrum disorders: some gender aspects. Res. Dev. Disabil. 33:5 (2012), 1642–1648.
50. [50] Rai, D., Lee, B.K., Dalman, C., Golding, J., Lewis, G., Magnusson, C., Parental depression, maternal antidepressant use during pregnancy, and risk of autism spectrum disorders: population based case-control study. BMJ, 346, 2013, f2059.
51. [51] Gidaya, N.B., Lee, B.K., Burstyn, I., Yudell, M., Mortensen, E.L., Newschaffer, C.J., In utero exposure to selective serotonin reuptake inhibitors and risk for autism spectrum disorder. J. Autism Dev. Disord. 44:10 (2014), 2558–2567.
52. [52] Harrington, R.A., Lee, L.C., Crum, R.M., Zimmerman, A.W., Hertz-Picciotto, I., Prenatal SSRI use and offspring with autism spectrum disorder or developmental delay. Pediatrics 133:5 (2014), e1241–1248.
53. [53] Hviid, A., Melbye, M., Pasternak, B., Use of selective serotonin reuptake inhibitors during pregnancy and risk of autism. N. Engl. J. Med. 369:25 (2013), 2406–2415.
54. [54] Sørensen, M.J., Grønborg, T.K., Christensen, J., et al. Antidepressant exposure in pregnancy and risk of autism spectrum disorders. Clin. Epidemiol. 5:1 (2013), 449–459.
55. [55] El Marroun, H., White, T.J., van der Knaap, N.J., et al. Prenatal exposure to selective serotonin reuptake inhibitors and social responsiveness symptoms of autism: population-based study of young children. Br. J. Psychiatry 205:2 (2014), 95–102.
56. [56] Boukhris, T., Sheehy, O., Mottron, L., Bérard, A., Antidepressant use during pregnancy and the risk of autism spectrum disorder in children. JAMA Pediatr. 170:2 (2016), 117–124.
57. [57] Man, K.K., Tong, H.H., Wong, L.Y., Chan, E.W., Simonoff, E., Wong, I.C., Exposure to selective serotonin reuptake inhibitors during pregnancy and risk of autism spectrum disorder inchildren: a systematic review and meta-analysis of observational studies. Neurosci. Biobehav. Rev. 49 (2015), 82–89.
58. [58] Tohru, T., Matsuyama, T., Koren, G., Takeuchi, M., Ito S: Risks of autism spectrum disorder in the offspring exposed to selective serotonin reuptake inhibitors in utero: a systematic review and meta-analysis. J. Popul. Ther. Clin. Pharmacol., 22, 2015, e148.
59. [59] Moher, D., Liberati, A., Tetzlaff, J., Altman, D.G., for the PRISMA Group: preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ, 339, 2009, b2535.
60. [60] Stroup, D.F., Berlin, J.A., Morton, S.C., et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting: meta-analysis of observational studies in epidemiology (MOOSE) group. JAMA 283:15 (2000), 2008–2012.
61. [61] Wells G, Shea B, O'Connell D, et al., The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. (accessed 21.01.16.).
62. [62] The Cochrane Collaboration. Cochrane handbook for systematic reviews of interventions, version 5.1.0. 2011. http://handbook.cochrane.org/chapter_9/9_4_3_2_the_generic_inverse_variance_outcome_type_in_revman.htm. (accessed 21.01.16.).
63. [63] Higgins, J.P., Thompson, S.G., Deeks, J.J., Altman, D.G., Measuring inconsistency in meta-analyses. BMJ 327:7414 (2003), 557–560.
64. [64] Lau, J., Ioannidis, J.P., Terrin, N., Schmid, C.H., Olkin, I., The case of the misleading funnel plot. BMJ 333:7568 (2006), 597–600.
65. [65] Hiemke, C., Härtter, S., Pharmacokinetics of selective serotonin reuptake inhibitors. Pharmacol. Ther. 85:1 (2000), 11–28.
66. [66] Strömland, K., Nordin, V., Miller, M., Akerström, B., Gillberg, C., Autism in thalidomide embryopathy: a population study. Dev. Med. Child Neurol. 36:4 (1994), 351–356.
67. [67] Narita, N., Kato, M., Tazoe, M., Miyazaki, K., Narita, M., Okado, N., Increased monoamine concentration in the brain and blood of fetal thalidomide- and valproic acid-exposed rat: putative animal models for autism. Pediatr. Res. 52:4 (2002), 576–579.
68. [68] Miyazaki, K., Narita, N., Narita, M., Maternal administration of thalidomide or valproic acid causes abnormal serotonergic neurons in the offspring: implication for pathogenesis of autism. Int. J. Dev. Neurosci. 23:2–3 (2005), 287–297.
69. [69] Harrington, R.A., Lee, L.C., Crum, R.M., Zimmerman, A.W., Hertz-Picciotto, I., Serotonin hypothesis of autism: implications for selective serotonin reuptake inhibitor use during pregnancy. Autism Res. 6:3 (2013), 149–168.
70. [70] Baldessarini, R.J., Drugs and the treatment of psychiatric disorders. Hardman, J.G., Limbird, L.E., Gilman, A.G., (eds.) Goodman & Gilman's The Pharmacological Basis Of Therapeutics, 10th ed., 2001, McGraw-Hill, New York, 447–484.
71. [71] Owens, M.J., Morgan, W.N., Plott, S.J., Nemeroff, C.B., Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites. J. Pharmacol. Exp. Ther. 283:3 (1997), 1305–1322.
72. [72] Kaplan, Y.C., Keskin-Arslan, E., Acar, S., Prenatal antidepressant use and risk of autism spectrum disorders in children. JAMA Pediatr., 170(7), 2016, 712.
73. [73] Malm, H., Brown, A.S., Gissler, M., et al. Gestational exposure to selective serotonin reuptake ınhibitors and offspring psychiatric disorders: a national register-based study. J. Am. Acad. Child Adolesc. Psychiatry 55:5 (2016), 359–366.
74. [74] Tick, B., Bolton, P., Happé, F., Rutter, M., Rijsdijk, F., Heritability of autism spectrum disorders: a meta-analysis of twin studies. J. Child Psychol. Psychiatry 57:5 (2016), 585–595.
75. [75] Colvert, E., Tick, B., McEwen, F., et al. Heritability of autism spectrum disorder in a uk population-based twin sample. JAMA Psychiatry 72:5 (2015), 415–423.
76. [76] Williams, K., Brignell, A., Randall, M., Silove, N., Hazell, P., Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD). Cochrane Database Syst. Rev.(8), 2013, D004677.
77. [77] Irl, C., Hasford, J., Assessing the safety of drugs in pregnancy: the role of prospective cohort studies. Drug Saf. 22:3 (2000), 169–177.
78. [78] Källén, B., The problem of confounding in studies of the effect of maternal drug use on pregnancy outcome. Obstet. Gynecol. Int., 2012, 2012, 148616.
79. [79] Mitchell, Allen A., Systematic identification of drugs that cause birth defects − a new opportunity. N. Engl. J. Med. 349:26 (2003), 2556–2559.
80. [80] Schaefer, C., Drug safety in pregnancy: utopia or achievable prospect? Risk information, risk research and advocacy in teratology information services. Congenit. Anom. (Kyoto) 51:1 (2011), 6–11.
81. [81] Ehrenstein, V., Sørensen, H.T., Bakketeig, L.S., Pedersen, L., Medical databases in studies of drug teratogenicity: methodological issues. Clin. Epidemiol. 2 (2010), 37–43.